Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA152943 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Expression data from EZH2 inhibitor treated Non-Hodgkins Lymphoma cell lines
| PRJNA213485 | ENA
Project description:Gene expression profiling of EZH2 mutant and wild type DLBCL cell lines treated with EZH2 inhibitor
| PRJNA175452 | ENA
Project description:Loss of H3K27me3 repressive chromatin histone marks, maintained by the histone methyltransferase (HKMT) EZH2, may lead to reversal of epigenetic silencing in tumor cells and have therapeutic potential. Using a cell-based assay, we have identified three compounds from a HKMT inhibitor chemical library which re-express H3K27me3 mediated, silenced genes. Chromatin immunoprecipitation verified a decrease in silencing marks (H3K27me3, H3K9me3) and importantly an increase in active marks (H3K4me2/3, H3K27ac) at the promoter of re-expressed genes. Compound treated breast tumor cells induced enrichment for genome-wide changes in expression of known target genes for EZH2 and induced cell growth inhibition: with most sensitive breast tumor cell lines having low EZH2 protein expression, while a normal epithelial breast line was least sensitive. Agilent SurePrint G3 Human 8x60k two-colour microarrays were used to profile gene expression changes induced by treatment with drug compounds in MDA MB-231 cells, both at 24h and 48h. 4 replicates were used for each drug, time combination. A separate untreated control sample was used for comparison with each replicate.
2013-08-27 | E-GEOD-36131 | biostudies-arrayexpress
Project description:Loss of H3K27me3 repressive chromatin histone marks, maintained by the histone methyltransferase (HKMT) EZH2, may lead to reversal of epigenetic silencing in tumor cells and have therapeutic potential. Using a cell-based assay, we have identified three compounds from a HKMT inhibitor chemical library which re-express H3K27me3 mediated, silenced genes. Chromatin immunoprecipitation verified a decrease in silencing marks (H3K27me3, H3K9me3) and importantly an increase in active marks (H3K4me2/3, H3K27ac) at the promoter of re-expressed genes. Compound treated breast tumor cells induced enrichment for genome-wide changes in expression of known target genes for EZH2 and induced cell growth inhibition: with most sensitive breast tumor cell lines having low EZH2 protein expression, while a normal epithelial breast line was least sensitive.
2013-08-27 | GSE36131 | GEO
Project description:Breast cancer cell lines treated with eribulin and paclitaxel
| PRJNA219068 | ENA
Project description:Expression data in NK150460 treated breast cancer cell lines
| PRJNA261441 | ENA
Project description:Expresssion data from reovirus treated breast cancer cell lines
| PRJNA286858 | ENA
Project description:DNA methyltransferase inhibitor 5-aza-dC-treated prostate cancer cell lines
| PRJNA95245 | ENA